PolyPid (PYPD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
PolyPid Ltd., a pharmaceutical company, has reported its interim condensed consolidated financial statements for the period ending June 30, 2024. The unaudited report highlights a total asset increase to $19,527 thousand from $15,372 thousand at the end of the previous year. Additionally, the company shows a shareholders’ equity of $1,601 thousand, recovering from a deficit position.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.